[
    {
        "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8#Head",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8",
                "http://www.nanopub.org/nschema#hasAssertion": [
                    {
                        "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8#assertion"
                    }
                ],
                "http://www.nanopub.org/nschema#hasProvenance": [
                    {
                        "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8#provenance"
                    }
                ],
                "http://www.nanopub.org/nschema#hasPublicationInfo": [
                    {
                        "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8#pubinfo"
                    }
                ],
                "@type": [
                    "http://www.nanopub.org/nschema#Nanopublication"
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8#provenance",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8#assertion",
                "http://www.w3.org/ns/prov#wasAttributedTo": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8#pubinfo",
        "@graph": [
            {
                "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8#sig",
                "http://purl.org/nanopub/x/hasAlgorithm": [
                    {
                        "@value": "RSA"
                    }
                ],
                "http://purl.org/nanopub/x/hasPublicKey": [
                    {
                        "@value": "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
                    }
                ],
                "http://purl.org/nanopub/x/hasSignature": [
                    {
                        "@value": "Z0p4ng4ay2tqerdaaoCmOrIr3hqPej9UFwlEJYUQGn85yaSJuI0TYa04j3Wdd7BPnPP+E9pP8wYHkqGdXoHroUA7bATCO+hKHcBsWlMnuvo4b6VZKp75q6aH/ARlXUqZRLFvcKgEh5Q0mOXa4Pg/j96+n+m4CNltTU/tmFASl1Y="
                    }
                ],
                "http://purl.org/nanopub/x/hasSignatureTarget": [
                    {
                        "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8",
                "http://purl.org/dc/terms/created": [
                    {
                        "@value": "2021-08-25T14:00:28.988+02:00",
                        "@type": "http://www.w3.org/2001/XMLSchema#dateTime"
                    }
                ],
                "http://purl.org/dc/terms/creator": [
                    {
                        "@id": "https://orcid.org/0000-0002-1468-3557"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate": [
                    {
                        "@id": "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate": [
                    {
                        "@id": "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
                    }
                ],
                "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate": [
                    {
                        "@id": "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
                    }
                ]
            }
        ]
    },
    {
        "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8#assertion",
        "@graph": [
            {
                "@id": "http://purl.obolibrary.org/obo/DOID_4989",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Disease"
                    }
                ]
            },
            {
                "@id": "http://purl.org/np/RAWIn9DX8f9Mjaky-kidQjmRfC4XM87tPVqcNN483K-o8#association",
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#object": [
                    {
                        "@id": "http://purl.obolibrary.org/obo/DOID_4989"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/treats"
                    }
                ],
                "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject": [
                    {
                        "@id": "https://identifiers.org/drugbank:DB00900"
                    }
                ],
                "@type": [
                    "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement"
                ],
                "http://www.w3.org/2000/01/rdf-schema#label": [
                    {
                        "@value": "\"Coadministration with stavudine allopurinol or ribavirin is contraindicated. ( 4 VIDEX EC is contraindicated when coadministered with the following medications:   Stavudine- potential for serious and/or life-threatening events, notably pancreatitis, lactic acidosis, hepatotoxicity, and peripheral neuropathy [ see  Warnings and Precautions 5.1 5.2 5.3 5.5   Allopurinol- systemic exposures of didanosine are increased, which may increase didanosine-associated toxicity [ see  Clinical Pharmacology (12.3)   Ribavirin- exposures of the active metabolite of didanosine (dideoxyadenosine 5'-triphosphate) are increased. Fatal hepatic failure, as well as peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis have been reported in patients receiving both didanosine and ribavirin.\""
                    }
                ],
                "https://w3id.org/biolink/vocab/provided_by": [
                    {
                        "@id": "https://w3id.org/um/NeuroDKG"
                    }
                ],
                "https://w3id.org/biolink/vocab/relation": [
                    {
                        "@id": "https://schema.org/MedicalContraindication"
                    }
                ]
            },
            {
                "@id": "https://identifiers.org/drugbank:DB00900",
                "https://w3id.org/biolink/vocab/category": [
                    {
                        "@id": "https://w3id.org/biolink/vocab/Drug"
                    }
                ]
            }
        ]
    }
]